MASCC

Multinational Association of Supportive Care in Cancer www.mascc.org

National Cancer Institute

www.cancer.gov

National Health Service UK

www.nhs.uk

UKOMiC

UK Oral Mucositis in Cancer Group
www.ukomic.co.uk

EOCC

European Oral Care in Cancer Group
Oral Care Guidance and Support
www.cancernurse.eu

LITERATUR

  1. Trotti, A., Bellm, L. A., Epstein, J. B., et al. (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol, 66(3):253–262.
  2. Wardley, A. M., Jayson, G. C., Swindell, R., et al. (2000) Prospective evaluation of OM in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol, 110(2):292–299.
  3. Sonis, S. T. (2004) Oral mucositis in cancer therapy. J Support Oncology, 2(3):3–8.
  4. Fulton, J. S., Middleton, G. J., McPhail, J. T. (2002) Management of oral complications. Semin Oncol Nurs, 18(1):28–35.
  5. Dodd, M. J., Miaskowski, C., Dibble, S. L., et al. (2000) Factors influencing OM in patients receiving chemotherapy. Cancer Pract, 8(6):291–297.
  6. Bruce, S. D., Quinn, A. (2007) US Oncological Disease, 1:86–90.
  7. Hadjieva, T., Cavallin-Ståhl, E., Linden, M. and Tiberg, F. (2014) Treatment of oral mucositis pain following radiation therapy for head-and-neck cancer using a bioadhesive barrier-forming lipid solution. Support Care Cancer, 22(6):1557–1562.
  8. Seidenspinner, I., Adamietz, I. A., Strohm, G. L. and Tiberg, F. (2015) Effects of episil® oral liquid in cancer patients with oral mucositis: an observational study. Poster vorgestellt auf der MASCC, 2015.
  9. Camurus. (2015) episil® Packungsbeilage.
  10. Murphy, B. A. (2007) Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol, 5(9 Suppl 4):13–21.
  11. Vera-Llonch, M., Oster, G., et al. (2006) Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer, 106(2):329–336.
  12. National Health Service. Ursachen für Mukositis. http://www.nhs.uk/conditions/mucositis/Pages/Causes.aspx. Letzter Zugriff 14. Juni 2015.
  13. UKOMiC OM Leitlinien. Leitlinien und Hilfestellung für die Mundversorgung bei der Krebsbehandlung und der palliativen Versorgung. http://www.ukomic.co.uk/pdf/UK_OM_Guidelines_v3.pdf. Letzter Zugriff 14. Juni 2015.
  14. Patent EP1848403. Topical Bioadhesive Formulations.
  15. Barauskas, J., Christerson, L., Wadsäter, M., et al, (2014) Bioadhesive Lipid Compositions: Self-Assembly Structures, Functionality, and Medical Applications. Mol. Pharmaceutics, 11(3):895−903.
  16. Svanberg, A., Birgegård, G., Öhrn, K. (2010) A new preventive strategy using a bioadhesive oromucosal lipid solution and oral cryotherapy to protect the oral cavity and reduce the need for total parenteral nutrition (TPN) for patients undergoing autologous stemcell transplantation. Support Care Cancer, 18, (Suppl. 3) S114.
  17. Cheng Y., Qin S.K., Chen Y.P., et al. (2018) Local analgesic effect of a bioadhesive barrier-forming oral liquid in cancer patients with oral mucositis caused by chemotherapy and/or radiotherapy: a randomised, multicenter, single-use, positive-controlled, open-label study. Onco Targets Ther. 11: 8555-8564
  18. Wei J., Wu J., Wang H., et al. (2021) A bioadhesive barrier-forming oral liquid gel improved oral mucositis and nutritional status in patients with head and neck cancers undergoing radiotherapy: A retrospective single center study, Front. Oncol., 11: 617392.